The aging of the population is a reality in our society, with a strong increase in the number of elderly patients hospitalized for heart failure in our institutions. Heart failure in these patients is more present than to younger patients, with preserved ejection fraction form (HFpEF). Aging is responsible for the onset of senile amyloid cardiomyopathy. This pathology is still imperfectly understood and its link with the increase in the frequency of HFpEF is important. In addition, specific treatments have just shown their effectiveness. It is therefore urgent to better identify the prognostic predictive parameters of this cardiomyopathy. The pathophysiological involvement of the coronary microcirculation responsible for a true microvascular coronary disease (CMVD) has been described as predictive factor in all cardiomyopathies. However the implementation of preventive strategies and / or therapeutic of the coronary microcirculation dysfunction are limited because we lack of diagnostic tests available and applicable to large cohorts of patients. Our team INSERM U1039 Radiopharmaceutiques Biocliniques in collaboration with the laboratory GIPSA-lab (Grenoble Images Speech Signal Automatique), laboratory specialized in the signal analysis, has developed a new method of analysis allowing to measure the coronary microcirculation dysfunction usable in SPECT thanks to the measurement of a myocardial perfusion heterogeneity index (IHPM) (patented technique). The 3C registry (NCT03479580) is a registry studying the prevalence and cardiovascular prognosis of macro and microcirculatory coronary artery disease using the latest coronary evaluation techniques in patient with cardiomyopathy. This registry deployed on interventional cardiology centers on the Alpine Arc is therefore also addressed to patients with senile cardiomyopathy. The data collected will provide a better understanding of the factors influencing the prognosis of senile cardiomyopathy and the prognostic contribution of the measurement of the IHPM will be evaluated.
Study Type
OBSERVATIONAL
Enrollment
142
Chu Grenoble Alpes
Grenoble, France
RECRUITINGPrognostic value of myocardial perfusion heterogeneity index on mortality at 1 year in patients with senile cardiac amyloidosis.
Rate of occurrence of the primary endpoint: all-cause mortality at 1 year
Time frame: 1 year
Prognostic value of IHMP on hospitalizations for heart failure in patients with senile cardiac amyloidosis.
Rate of secondary endpoint: hospitalization for heart failure
Time frame: 1 year
Prognostic value of IHPM on the quality of life in patients with senile cardiac amyloidosis
Minnesota Quality of Life Questionnaire
Time frame: 1 year
Relationships between IHPM and structural and functional measures in cardiac imaging in cardiac ultrasound
Measurements in cardiac echography (longitudinal, radial and circumferential strain of the left ventricle in speckle tracking, left atrial strain in speckle tracking)
Time frame: Inclusion
Relationships between IHPM and structural and functional measures in cardiac imaging in MRI.
Measurement of IHPM in scintigraphy and measurements in cardiac MRI (right and left ventricular function, cardiac mass,% LV fibrosis).
Time frame: Inclusion
Correlations between IHMP and geriatric frailty.
grid SEGA-A (short emergency geriatric evaluation)
Time frame: Inclusion
Relationships between IHPM in cardiac scintigraphy and the rhythmic evaluations.
Abnormality on holter frequency (atrial fibrillation and / or bradycardia requiring pacemaker implantation).
Time frame: inclusion
Comparison of IHPM between patients with amyloid senile cardiomyopathy and a control population paired with age and sex.
Measurement of IHPM in myocardial scintigraphy in patients with senile cardiac amyloidosis and a control population paired with age and sex.
Time frame: Inclusion
Side effect of tafamidis in this population
Rate of side effect in function of phenotype of patients (imaging, geriatric evaluation)
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.